These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29366782)

  • 1. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
    Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
    Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
    Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
    McFaline-Figueroa JL; Braun CJ; Stanciu M; Nagel ZD; Mazzucato P; Sangaraju D; Cerniauskas E; Barford K; Vargas A; Chen Y; Tretyakova N; Lees JA; Hemann MT; White FM; Samson LD
    Cancer Res; 2015 Aug; 75(15):3127-38. PubMed ID: 26025730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
    Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
    Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
    Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
    J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
    Ramirez YP; Mladek AC; Phillips RM; Gynther M; Rautio J; Ross AH; Wheelhouse RT; Sakaria JN
    Mol Cancer Ther; 2015 Jan; 14(1):111-9. PubMed ID: 25351918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
    Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
    Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.